Gland Pharma has updated its schedule of analyst and institutional investor meetings for September 2026. The company added a one-on-one session with Kotak Mutual Fund on September 9, 2026, to its existing engagement calendar.

The disclosure was issued on September 4, 2026, pursuant to Regulation 30 read with Part A of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015. This filing ensures transparency regarding the firm's interactions with market participants during the specified period.

Updated Meeting Schedule

The revised calendar now includes the additional engagement with Kotak Mutual Fund alongside previously announced meetings with Carnelian Capital, First Ray Capital, WCM Investment, LIC MF, ICICI Securities, and JP Morgan. The company will also participate in the BofA Securities 2026 Asia Pacific Conference from September 21 to September 22.

Regulatory Disclosure

The company noted that the schedule is subject to change due to exigencies on the part of the investors, analysts, or the company itself. Sampath Kumar Pallerlamudi, Company Secretary and Compliance Officer, signed the disclosure.

Gland Pharma received a clean outcome from the US Food and Drug Administration after an inspection of its VSEZ sterile oncology facility concluded with zero Form 483 observations. The inspection ran from August 24 to September 1, 2026.

Regulatory inspection outcome

A Form 483 is issued by the USFDA when investigators observe conditions that may constitute violations of the Food Drug and Cosmetic Act during a facility inspection. Receiving zero observations indicates that inspectors identified no such conditions at the VSEZ sterile oncology site, reflecting the facility's adherence to current Good Manufacturing Practice standards.

Significance for the VSEZ facility

The VSEZ facility is dedicated to sterile oncology products, a high-complexity, high-scrutiny manufacturing segment that demands rigorous quality and compliance controls. A clean USFDA inspection outcome at such a facility underscores the robustness of Gland Pharma's quality systems at this unit.

The absence of Form 483 observations is among the most favourable outcomes a pharmaceutical manufacturer can receive from a USFDA inspection, as it indicates no objectionable conditions were noted during the review.